Cover Image

Definitive radiotherapy for squamous cell carcinoma of the oral cavity: a single-institution experience

Background - Surgery is standard of care for oral cavity cancer (OCC). We provide a single-institution experience using definitive radiotherapy (RT) with or without concurrent systemic therapy for primary unresectable OCC. - - Patients and methods - We retrospectively examined 49 patients with non-...

Full description

Saved in:
Bibliographic Details
Main Authors: Uzun-Lang, Kristin (Author) , Baur, Melissa (Author) , Held, Thomas (Author) , El-Shafie, Rami (Author) , Moratin, Julius (Author) , Freudlsperger, Christian (Author) , Plath, Karim (Author) , Bougatf, Nina (Author) , Hoffmann, Jürgen (Author) , Plinkert, Peter K. (Author) , Debus, Jürgen (Author) , Adeberg, Sebastian (Author)
Format: Article (Journal)
Language:English
Published: 19 Nov 2021
In: Radiology and oncology
Year: 2021, Volume: 55, Issue: 4, Pages: 467-473
ISSN:1581-3207
DOI:10.2478/raon-2021-0041
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.2478/raon-2021-0041
Verlag, lizenzpflichtig, Volltext: https://www.sciendo.com/article/10.2478/raon-2021-0041
Get full text
Author Notes:Kristin Lang, Melissa Baur, Thomas Held, Rami El Shafie, Julius Moratin, Christian Freudlsperger, Karim Zaoui, Nina Bougatf, Jürgen Hoffmann, Peter K. Plinkert, Jürgen Debus, Sebastian Adeberg
Description
Summary:Background - Surgery is standard of care for oral cavity cancer (OCC). We provide a single-institution experience using definitive radiotherapy (RT) with or without concurrent systemic therapy for primary unresectable OCC. - - Patients and methods - We retrospectively examined 49 patients with non-metastatic primary unresectable OCC treated with definitive RT between 2000 and 2019. The majority of patients (63.3%) were treated with definitive chemoradiotherapy while 26.5% were given single-agent cetuximab weekly simultaneous to definitive RT. Five patients were treated with definitive RT alone because of limited disease and no nodal involvement. - - Results - Median follow-up was 73 months (range, 6-236 months), median progression free survival (PFS) was 42 months (range, 2-157 months), median local disease-free survival (LDFS) was 44 months (range, 2-157 months) and median overall survival (OS) from the time of RT initiation was 52 months (range, 5-236 months). There were 65.3% locoregional failures, 84.4% local and 15.6% distant metastasis. The majority of patients with local failure presented with American Joint Committee on Cancer (AJCC) Stage III-IV disease (59.2%). The 5-year Kaplan-Meier estimates for OS (III-IV vs. I-II) was 22.8% vs. 54.2 % (p = 0.03, HR 2.090, 1.1-4.2). Patients who were treated with systemic therapy had a significant better 5-year overall survival compared to those with RT
Item Description:Gesehen am 20.12.2021
Physical Description:Online Resource
ISSN:1581-3207
DOI:10.2478/raon-2021-0041

Similar Items